Govt Job Portal to get info about latest Govt Jobs in India.10th, 12th pass Govt jobs.Best courses after 12th class. Defense ...

Reliable access to medicines has always mattered, but in today’s healthcare environment it has become a defining issue for pharmacy operations and patient care. Drug shortages, supply disruptions, and ...

The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

Execution infrastructure converts early commercial and supply signals into owned, cross-functional workflows with decision logic and closure tracking, preventing insights from stalling in dashboards.

The Trump administration has expanded TrumpRx to include more than 600 generic medications — a significant scale-up from the platform’s original focus on branded drugs under most-favored-nation ...

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Subscribe to read this story ad-free Get unlimited access to ...

Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

WASHINGTON, April 29 (Reuters) - The U.S. Supreme Court on Wednesday heard a patent dispute over a generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular drug Vascepa that could ...

Analysts will be watching as a generic version of semaglutide—marketed by Novo Nordisk as Wegovy for weight loss—launches in Canada as a test case for future price erosion in the U.S. A generic ...

Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.